Specific features of pharmacokinetics in children

References

• Alcorn J, McNamara PJ. (2003). Pharmacokinetics in the newborn. Adv Drug Deliv Rev 55:667–686.
   PubMed Web of Science ®Google Scholar
• Algren A. (2008). Review of N-acetylcysteine for the treatment of acetaminophen (paracetamol) toxicity in pediatrics. Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. Geneva, 29 Sep–3 Oct. [Online] Available from: http://www.who.int/selection_medicines/committees/subcommittee/2/acetylcysteine_rev.pdf [last accessed 29 Oct 2015].
   Google Scholar
• Allegaert K, van de Velde M, van den Anker J. (2014). Neonatal clinical pharmacology. Paediatr Anaesth 24:30–38.
   PubMed Web of Science ®Google Scholar
• Amato M, Hüppi P, Isenschmid M, Schneider H. (1992). Developmental aspects of percutaneous caffeine absorption in premature infants. Am J Perinatol 9:431–434.
   PubMed Web of Science ®Google Scholar
• Anderson GD. (2010). Developmental pharmacokinetics. Semin Pediatr Neurol 17:208–213.
   PubMed Web of Science ®Google Scholar
• Anzenbacher P, Zanger UM. (2012). Metabolism of drugs and other xenobiotics. 1st ed. Weinheim, Germany: Wiley-VCH.
   Google Scholar
• Armstrong SC, Cozza KL. (2003). Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality, Part II. Psychosomatics 44:515–520.
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. (2006). Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 45:1077–1097.
   PubMed Web of Science ®Google Scholar
• Blake MJ, Abdel-Rahman SM, Pearce RE, et al. (2006). Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res 60:717–723.
   PubMed Web of Science ®Google Scholar
• Bowles A, Keane J, Ernest T, et al. (2010). Specific aspects of gastro-intestinal transit in children for drug delivery design. Int J Pharm 395:37–43.
   PubMed Web of Science ®Google Scholar
• Brion LP, Fleischman AR, Schwartz GJ. (1991). Gentamicin interval in newborn infants as determined by renal function and postconceptional age. Pediatr Nephrol 5:675–679.
   PubMed Web of Science ®Google Scholar
• Buzková H, Pechandová K, Slanar O, Perlík F. (2008). Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population. Cell Biochem Funct 26:76–81.
   PubMed Web of Science ®Google Scholar
• Cashman JR, Zhang J. (2006). Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 46:65–100.
   PubMed Web of Science ®Google Scholar
• Clarke DJ, Moghrabi N, Monaghan G, et al. (1997). Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-haemolytic unconjugated hyperbilirubinaemias. Clin Chim Acta 266:63–74.
   PubMed Web of Science ®Google Scholar
• Clement B, Lustig KL, Zeigler DM. (1993). Oxidation of desmethylpromethazine catalyzed by pig liver flavin-containing monooxygenase. Number and nature of metabolites. Drug Metab Dispos 21:24–29.
   PubMed Web of Science ®Google Scholar
• Coen M. (2015). Metabolic phenotyping applied to pre-clinical and clinical studies of acetaminophen metabolism and hepatotoxicity. Drug Metab Rev 47:29–44.
   PubMed Web of Science ®Google Scholar
• de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. (1999). Cytochrome P450 3A: Ontogeny and drug disposition. Clin Pharmacokinet 37:485–505.
   PubMed Web of Science ®Google Scholar
• Ehrnebo M, Agurell S, Jalling B, Boréus LO. (1971). Age differences in drug binding by plasma proteins: Studies on human foetuses, neonates and adults. Eur J Clin Pharmacol 3:189–193.
   PubMed Web of Science ®Google Scholar
• Flockhart DA. (2007). Drug interactions: Cytochrome P450 drug interaction table. Indiana University School of Medicine. [Online]. Available from: http://medicine.iupui.edu/clinpharm/ddis/clinical-table/ [last accessed 1 May 2015].
   Google Scholar
• Gerónimo-Pardo M, Cuartero-del-Pozo AB, Jiménez-Vizuete JM, et al. (2005). Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock. Ann Pharmacother 39:538–542.
   PubMed Web of Science ®Google Scholar
• Ghosal A, Gupta S, Ramanathan R, et al. (2009). Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett 3:162–170.
   PubMedGoogle Scholar
• Gilbert A, Lereboullet P. (1901). La cholemie simple familiale. Sem Med 21:241–243.
   Google Scholar
• Guengerich FP. (2003). Cytochromes P450, drugs, and diseases. Mol Interv 3:194–204.
   PubMedGoogle Scholar
• Hakkola J, Pasanen M, Purkunen R, et al. (1994). Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem Pharmacol 48:59–64.
   PubMed Web of Science ®Google Scholar
• Hines RN. (2008). The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2:250–267.
   Web of Science ®Google Scholar
• Ingelman-Sundberg M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13.
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. (2003). CYP2D6 and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197–204.
   Google Scholar
• Jancova P, Anzenbacher P, Anzenbacherova E. (2010). Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:103–116.
   PubMed Web of Science ®Google Scholar
• Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. (2002). Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 71:21–29.
   PubMed Web of Science ®Google Scholar
• Johnson TN. (2003). The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 192:37–48.
   PubMed Web of Science ®Google Scholar
• Johnsrud EK, Koukouritaki SB, Divakaran K, et al. (2003). Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther 307:402–407.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. (2003). Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157–1167.
   PubMed Web of Science ®Google Scholar
• Kiang TK, Ensom MH, Chang TK. (2005). UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97–132.
   PubMed Web of Science ®Google Scholar
• Koren G. (1997). Therapeutic drug monitoring principles in the neonate. National Academy of Clinical Biochemistry. Clin Chem 43:222–227.
   PubMed Web of Science ®Google Scholar
• Koren G, Cairns J, Chitayat D, et al. (2006). Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368:704.
   PubMed Web of Science ®Google Scholar
• Koukouritaki SB, Simpson P, Yeung CK, et al. (2002). Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 51:236–243.
   PubMed Web of Science ®Google Scholar
• Koukouritaki SB, Manro JR, Marsh SA, et al. (2004). Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 308:965–974.
   PubMed Web of Science ®Google Scholar
• Kraus DM, Fischer JH, Reitz SJ, et al. (1993). Alterations in theophylline metabolism during the first year of life. Clin Pharmacol Ther 54:351–359.
   PubMed Web of Science ®Google Scholar
• Krueger SK, Williams DE. (2005). Mammalian flavin-containing monooxygenases: Structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 106:357–387.
   PubMed Web of Science ®Google Scholar
• Lacroix D, Sonnier M, Moncion A, et al. (1997). Expression of CYP3A in the human liver–evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247:625–634.
   PubMedGoogle Scholar
• Lin JH, Yamazaki M. (2003). Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin Pharmacokinet 42:59–98.
   PubMed Web of Science ®Google Scholar
• Livezey MR1, Briggs ED, Bolles AK, et al. (2014). Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica 44:309–319.
   PubMed Web of Science ®Google Scholar
• Lu H, Rosenbaum S. (2014). Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther 19:262–276.
   PubMedGoogle Scholar
• Mahmood I. (2014). Dosing in children: A critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet 53:327–346.
   PubMed Web of Science ®Google Scholar
• McCarver DG, Hines RN. (2002). The ontogeny of human drug-metabolizing enzymes: Phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 300:361–366.
   PubMed Web of Science ®Google Scholar
• McNamara PJ, Alcorn J. (2002). Protein binding predictions in infants. AAPS PharmSci 4:E4.
   PubMedGoogle Scholar
• Moree WJ, Li BF, Zamani-Kord S, et al. (2010). Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia. Bioorg Med Chem Lett 20:5874–5878.
   PubMed Web of Science ®Google Scholar
• Murry DJ, Crom WR, Reddick WE, et al. (1995). Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 23:1110–1116.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yokoi T, Inoue K, et al. (1996). CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics 5:449–457.
   Google Scholar
• Noda T, Todani T, Watanabe Y, Yamamoto S. (1997). Liver volume in children measured by computed tomography. Pediatr Radiol 27:250–252.
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Säwe J, Kager L, Rane A. (1982). Morphine glucuronidation in human fetal and adult liver. Eur J Clin Pharmacol 22:553–558.
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Turpeinen M, Hakkola J, et al. (2008). Inhibition and induction of human cytochrome P450 enzymes: Current status. Arch Toxicol 82:667–715.
   PubMed Web of Science ®Google Scholar
• Rakhmanina NY, van den Anker JN. (2006). Pharmacological research in pediatrics: From neonates to adolescents. Adv Drug Deliv Rev 20 58:4–14.
   PubMed Web of Science ®Google Scholar
• Ring JA, Ghabrial H, Ching MS, et al. (1999). Fetal hepatic drug elimination. Pharmacol Ther 84:429–445.
   PubMed Web of Science ®Google Scholar
• Rodbro P, Krasilnikoff PA, Christiansen PM. (1967). Parietal cell secretory function in early childhood. Scand J Gastroenterol 2:209–213.
   PubMedGoogle Scholar
• Seyberth HW, Rane A, Schwab M. (2011). Pediatric clinical pharmacology. Heidelberg, Germany: Springer.
   Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423.
   PubMed Web of Science ®Google Scholar
• Shou M, Korzekwa KR, Crespi CL, et al. (1994). The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol. Mol Carcinog 10:159–168.
   PubMed Web of Science ®Google Scholar
• Silverio J, Poole JW. (1973). Serum concentrations of ampicillin in newborn infants after oral administration. Pediatrics 51:578–580.
   PubMed Web of Science ®Google Scholar
• Sneitz N, Court MH, Zhang X, et al. (2009). Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3. Pharmacogenet Genomics 19:923–934.
   PubMed Web of Science ®Google Scholar
• Sonnier M, Cresteil T. (1998). Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 251:893–898.
   PubMedGoogle Scholar
• Stamer UM, Stüber F. (2007). Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype. Anaesthesia 62:1294–1295.
   PubMed Web of Science ®Google Scholar
• Stevens JC, Hines RN, Gu C, et al. (2003). Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 307:573–582.
   PubMed Web of Science ®Google Scholar
• Stevens JC, Marsh SA, Zaya MJ, et al. (2008). Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos 36:1587–1593.
   PubMed Web of Science ®Google Scholar
• Stockmann C, Constance JE, Roberts JK, et al. (2014). Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Clin Pharmacokinet 53:429–454.
   PubMed Web of Science ®Google Scholar
• Sunderland JM. (1959). Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. Am J Dis Child 97:761–767.
   Google Scholar
• Tassaneeyakul W, Mohamed Z, Birkett DJ, et al. (1992). Caffeine as a probe for human cytochromes P450: Validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2:173–183.
   PubMedGoogle Scholar
• Tsai C, Ahdab-Barmada M, Daood MJ, Watchko JF. (2001). P-glycoprotein expression in the developing human central nervous system: Cellular and tissue localization. Pediatr Res 47:436A.
   Google Scholar
• van den Anker JN, Schoemaker RC, Hop WC, et al. (1995). Ceftazidime pharmacokinetics in preterm infants: Effects of renal function and gestational age. Clin Pharmacol Ther 58:650–659.
   PubMed Web of Science ®Google Scholar
• Vieira I, Sonnier M, Cresteil T. (1996). Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 238:476–483.
   PubMedGoogle Scholar
• Weiss CF, Glasko AJ, Weston JK. (1960). Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses. N Engl J Med 262:787–794.
   PubMed Web of Science ®Google Scholar
• Yaffe SJ, Aranda JV. (2011). Neonatal and pediatric pharmacology. 4th edition. Philadelphia (PA): Lippincott Williams & Wilkins.
   Google Scholar
• Yang HY, Namkung MJ, Juchau MR. (1995). Expression of functional cytochrome P4501A1 in human embryonic hepatic tissues during organogenesis. Biochem Pharmacol 49:717–726.
   PubMed Web of Science ®Google Scholar
• Yeung CK, Lang DH, Thummel KE, Rettie AE. (2000). Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab Dispos 28:1107–1111.
   PubMed Web of Science ®Google Scholar
• Yokoi T. (2009). Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children. J Toxicol Sci 34:P307–SP312.
   Google Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141.
   PubMed Web of Science ®Google Scholar